Nuclear Medicine Technology Progress Report for Quarter Ending June 30, 1980 (open access)

Nuclear Medicine Technology Progress Report for Quarter Ending June 30, 1980

Results of experiments demonstrated that the alkyl portion of 9-telluraheptadecanoic acid (9-THDA) is retained in the myocardial tissue of rats to the same extent as radioactivity from /sup 123m/Te-9-THDA. Tissue distribution experiments in rats one hr after injection of 10-(/sup 14/C)-9-telluraheptadecanoic acid were compared with the results of a parallel study using /sup 123m/Te-9-THDA. The results indicate that the alkyl region of 9-THDA is retained in the myocardium and that labeling of this portion of the 9-THDA molecule with radiohalogens such as /sup 123/I may be an attractive approach for evaluation of myocardial function. Results of preliminary studies for the development of radiolabeled barbiturates as a new class of agents for the measurement of regional blood perfusion in the brain are also described. Several new barbiturates substituted at the C-5 position were prepared and characterized. These compounds will be labeled with /sup 117m/Sn, /sup 75/Se, and /sup 123m/Te and brain uptake studies performed in rats. Studies of arsenic trioxide (As/sub 2/O/sub 3/) toxicity for human cells in the diffusion chamber assay system have continued. Studies employing /sup 74/As/sub 2/O/sub 3/ have demonstrated that uptake of radioactivity from test substances administered to rats can be detected in cells taken from the …
Date: January 1, 1981
Creator: Knapp, Furn F., Jr.
System: The UNT Digital Library